Table 1.

Clinical presentations and laboratory values of the patients described in the literature with COVID associated TTP.

		Albiol et al.	ALtowyan et al.	Beaulieu et al.	Hindilerden et al.	Marco et al.	Nicolotti et al.
Clinical presentation	Age (Years)	57	39	70	74	55	44
	Gender	F	M	M	F	F	F
	Fever	Yes	No	No	No	No	No
	CNSa	No	Yes	Yes	Yes	Yes	Yes
	O2 requirement	No	No	No	NAb	HFNCc 15 L/min	35% O2
	Time of TTPd diagnosis since COVID-19 detection	9 days	Same day	19 days	Same day	1 Month	2 days
	History of TMAe	No	No	No	No	Yes	No
Laboratory values at presentation	Hemoglobin	9.9 g/dL	6.7 g/dL	6 g/dL	6.6 g/dL	7.4 g/dL	6 g/dL
	Platelet	22 × 109/L	6 × 109/L	18 × 109/L	48 × 109/L	14 × 109/L	7 × 109/L
	Serum Creatinine	0.8 mg/dL	0.87 mg/dL	Normal (Level NA)	NA	3.18 mg/dL	2.3 mg/dL
	Schistocyte count (%)	6%	9%	NA	NA	NA	NA
	PLASMIC score	NA	6	NA	NA	NA	NA
	ADAMTS13 activity	2%	NA	<10%	0.2%	Undetectable	<5%
	ADAMTS 13 inhibitor	5.2 BU	NA	Weakly positive (1/2 titer)	>90 U/ml	31 U/ml	57 U/ml
Treatment	Recovery	Complete	Complete but prolonged	Complete	Complete	Complete but prolonged	Complete but prolonged
	Treatment	FFPf + PLEXg	Methylprednisolone, PLEX and Rituximab	Methylprednisolone and PLEX	Methylprednisolone and PLEX	FFP → steroids + PLEX and Caplacizumab	FFP → Methylprednisolone, PLEX and Rituximab → Caplacizumab

^aCentral nervous system.

^bNot available.

^cHigh flow nasal canula.

^dThrombotic thrombocytopenic purpura.

^eThrombotic microangiopathy.

^fFresh frozen plasma.

^gPlasma exchange.